

## Refine Search

### Search Results -

Terms	Documents
pyrogallol adj8 cyclic and L6	5

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L7





### Search History

DATE: Thursday, January 11, 2007    [Purge Queries](#)    [Printable Copy](#)    [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
<u>L7</u>	pyrogallol adj8 cyclic and l6	5	<u>L7</u>
<u>L6</u>	L5 and (treat\$7 or infect\$7)	76	<u>L6</u>
<u>L5</u>	L3 and (hiv or aids)	80	<u>L5</u>
<u>L4</u>	L3 and phenyl tetramer	1	<u>L4</u>
<u>L3</u>	L2 and cyclic	192	<u>L3</u>
<u>L2</u>	L1 and (514/\$ or 562/\$)	469	<u>L2</u>
<u>L1</u>	pyrogallol	13290	<u>L1</u>

END OF SEARCH HISTORY

## Hit List

First Hit

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

**Search Results - Record(s) 1 through 5 of 5 returned.**☐ 1. Document ID: US 20050288228 A1

L7: Entry 1 of 5

File: PGPB

Dec 29, 2005

PGPUB-DOCUMENT-NUMBER: 20050288228

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050288228 A1

TITLE: Bile-acid conjugates for providing sustained systemic concentrations of drugs

PUBLICATION-DATE: December 29, 2005

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Cundy, Kenneth C.	Redwood City	CA	US
Gallop, Mark A.	Los Altos	CA	US

US-CL-CURRENT: 514/12; 514/169, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	--------

☐ 2. Document ID: US 20020142998 A1

L7: Entry 2 of 5

File: PGPB

Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142998

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020142998 A1

TITLE: Bile-acid conjugates for providing sustained systemic concentrations of drugs

PUBLICATION-DATE: October 3, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Cundy, Kenneth C.	Redwood City	CA	US
Gallop, Mark A.	Los Altos	CA	US

US-CL-CURRENT: 514/169; 514/182, 552/515, 552/540

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20020099041 A1

L7: Entry 3 of 5

File: PGPB

Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020099041

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020099041 A1

TITLE: Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs

PUBLICATION-DATE: July 25, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Gallop, Mark A.	Los Altos	CA	US
Cundy, Kenneth C.	Redwood City	CA	US

US-CL-CURRENT: 514/169

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 7144877 B2

L7: Entry 4 of 5

File: USPT

Dec 5, 2006

US-PAT-NO: 7144877

DOCUMENT-IDENTIFIER: US 7144877 B2

TITLE: Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs

## PRIOR-PUBLICATION:

DOC-ID	DATE
US 20020099041 A1	July 25, 2002

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 6984634 B2

L7: Entry 5 of 5

File: USPT

Jan 10, 2006

US-PAT-NO: 6984634

DOCUMENT-IDENTIFIER: US 6984634 B2

TITLE: Bile-acid conjugates for providing sustained systemic concentrations of drugs

## PRIOR-PUBLICATION:

DOC-ID

US 20020142998 A1



DATE

October 3, 2002

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Attachments	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	----------	-------------	--------	------	----------

Terms	Documents
pyrogallol adj8 cyclic and L6	5

**Display Format:** [Previous Page](#)[Next Page](#)[Go to Doc#](#)



chain nodes :

14 15 16 17 18 32 33 34 35 36 50 51 52 53 54 68 69 70 71 72

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 19 20 21 22 23 24 25 26 27 28 29 30 31 37 38 39  
40 41 42 43 44 45 46 47 48 49 55 56 57 58 59 60 61 62 63 64 65 66 67

chain bonds :

3-16 4-15 5-17 7-18 10-13 13-14 21-34 22-33 23-35 25-36 28-31 31-32 39-52 40-51 41-53  
43-54 46-49 49-50 57-70 58-69 59-71 61-72 64-67 67-68

ring bonds :

1-2 1-6 2-3 2-31 3-4 4-5 5-6 6-13 7-8 7-12 8-9 9-10 10-11 11-12 13-38 19-20 19-24 20-21  
20-67 21-22 22-23 23-24 24-31 25-26 25-30 26-27 27-28 28-29 29-30 37-38 37-42 38-39 39-40  
40-41 41-42 42-49 43-44 43-48 44-45 45-46 46-47 47-48 49-56 55-56 55-60 56-57 57-58 58-59  
59-60 60-67 61-62 61-66 62-63 63-64 64-65 65-66

exact/norm bonds :

2-31 3-16 4-15 5-17 6-13 13-38 20-67 21-34 22-33 23-35 24-31 39-52 40-51 41-53 42-49 49-56  
57-70 58-69 59-71 60-67

exact bonds :

7-18 10-13 13-14 25-36 28-31 31-32 43-54 46-49 49-50 61-72 64-67 67-68

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 19-20 19-24 20-21 21-22 22-23  
23-24 25-26 25-30 26-27 27-28 28-29 29-30 37-38 37-42 38-39 39-40 40-41 41-42 43-44 43-48  
44-45 45-46 46-47 47-48 55-56 55-60 56-57 57-58 58-59 59-60 61-62 61-66 62-63 63-64 64-65  
65-66

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:CLASS15:CLASS16:CLASS17:CLASS18:CLASS19:Atom 20:Atom 21:Atom 22:Atom 23:Atom  
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS33:CLASS34:CLASS  
35:CLASS36:CLASS37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom  
46:Atom 47:Atom 48:Atom 49:Atom 50:CLASS51:CLASS52:CLASS53:CLASS54:CLASS55:Atom 56:Atom  
57:Atom 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom 64:Atom 65:Atom 66:Atom 67:Atom  
68:CLASS69:CLASS70:CLASS71:CLASS72:CLASS

PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN  
has been enhanced and reloaded  
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 6 NOV 10 CA/Caplus F-Term thesaurus enhanced  
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version  
8.01c now available  
NEWS 8 NOV 20 CAS Registry Number crossover limit increased to 300,000 in  
additional databases  
NEWS 9 NOV 20 CA/Caplus to MARPAT accession number crossover limit increased  
to 50,000  
NEWS 10 DEC 01 CAS REGISTRY updated with new ambiguity codes  
NEWS 11 DEC 11 CAS REGISTRY chemical nomenclature enhanced  
NEWS 12 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated  
NEWS 13 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and  
functionality  
NEWS 14 DEC 18 CA/Caplus pre-1967 chemical substance index entries enhanced  
with preparation role  
NEWS 15 DEC 18 CA/Caplus patent kind codes updated  
NEWS 16 DEC 18 MARPAT to CA/Caplus accession number crossover limit increased  
to 50,000  
NEWS 17 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 18 DEC 27 CA/Caplus enhanced with more pre-1907 records  
NEWS 19 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:11:54 ON 11 JAN 2007.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 12:12:07 ON 11 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jan 2007 VOL 146 ISS 3  
FILE LAST UPDATED: 10 Jan 2007 (20070110/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=>

Uploading C:\Program Files\Stnexp\Queries\060.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 12:12:39 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 161 TO ITERATE

100.0% PROCESSED 161 ITERATIONS

23 ANSWERS

SEARCH TIME: 00.00.01

L2 23 SEA SSS FUL L1

L3 5 L2

=> s l3 and py<2003

22868731 PY<2003

L4 2 L3 AND PY<2003



=> d 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:428850 CAPLUS

DOCUMENT NUMBER: 137:6006

TITLE: Preparation of Calixarenes as Anti-viral compounds

INVENTOR(S): Harris, Stephen J.

PATENT ASSIGNEE(S): Aids Care Pharma Limited, Ire.

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044121	A1	20020606	WO 2001-IE150	20011130 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002020992	A5	20020611	AU 2002-20992	20011130 <--
EP 1345884	A1	20030924	EP 2001-998526	20011130
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			IE 2000-983	A 20001201
			WO 2001-IE150	W 20011130
OTHER SOURCE(S):	CASREACT 137:6006; MARPAT 137:6006			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1 = OCH2CO2K, OCH2CO2H or OCH2CONH2; R2 = R1 or NO2; R3 = H, 2-HO2CCH2OC6H4, or 4-XC6H4 where X = halo (preferably F or Br); R4 = H or halo (preferably Br)] are prepared and disclosed as antiviral agents. Thus, II was prepared in four steps via cyclocondensation 4-fluorobenzaldehyde with pyrogallol and subsequent bromination, O-alkylation with Et bromoacetate and hydrolysis with KOH. II possessed a therapeutic index (TC50/EC50  $\mu$ m) of 4,000. I were found to have an additive effect when administered with AZT, and therefore, the compds. are useful as pharmaceutical compns. in the treatment of AIDS.

IT 433334-86-2P 433334-87-3P 433334-88-4P



433334-94-2P 433334-95-3P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediates; preparation and antiviral activity of calixarenes as anti-AIDS agents)


RN 433334-86-2 CAPLUS

CN Pentacyclo[19.3.1.13,7.19,13.115,19]octacos-1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-4,5,6,10,11,12,16,17,18,22,23,24-dodecol, 2,8,14,20-tetrakis(4-fluorophenyl)- (9CI) (CA INDEX NAME)







—OEt




RN 433334-94-2 CAPLUS  
 CN Pentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-4,5,6,10,11,12,16,17,18,22,23,24-dodecol,2,8,14,20-tetrakis(4-bromophenyl)- (9CI) (CA INDEX NAME)



RN 433334-95-3 CAPLUS  
 CN Pentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-4,5,6,10,11,12,16,17,18,22,23,24-dodecol,25,26,27,28-tetrabromo-2,8,14,20-tetrakis(4-bromophenyl)- (9CI) (CA INDEX NAME)





The chemical structure is a macrocycle consisting of four benzene rings connected by four methylene (-CH<sub>2</sub>-) bridges. Each of the four benzene rings has a bromine (Br) atom at the 1-position. The other three positions on each benzene ring are occupied by carboxymethoxy (-OCH<sub>2</sub>CO<sub>2</sub>H) groups. The carboxymethoxy groups are arranged such that they point outwards from the macrocycle, and the bromine atoms are also outwards. The overall structure is highly symmetrical.




● 12 K

RN	433334-85-1 CAPLUS
CN	Acetamide, 2,2',2'',2''',2'''',2''''',2''''',2''''',2''''',2''''', ',2''''''''',2'''''''''-[25,26,27,28-tetrabromo-2,8,14,20-tetrakis(4- bromophenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacosan- 1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene- 4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis- (9CI) (CA INDEX NAME)





NH<sub>2</sub>



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1995:994163 CAPLUS  
 DOCUMENT NUMBER: 124:55584  
 TITLE: Preparation of calixarene-based compounds having antibacterial, antifungal, anticancer, and anti-HIV activity  
 INVENTOR(S): Harris, Stephen J.  
 PATENT ASSIGNEE(S): Ire.  
 SOURCE: PCT Int. Appl., 148 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9519974	A2	19950727	WO 1995-IE8	19950124 <--
WO 9519974	A3	19950921		
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, FI, GB, HU, JP, KP, LU, NO, RO, UA, US				
RW: AT, BE, CH, DE, ES, FR, GB, GR, IE, LU, NL, SE, GA, ML, NE, SN, TD, TG				
AU 9515453	A	19950808	AU 1995-15453	19950124 <--
PRIORITY APPLN. INFO.:			IE 1994-57	A 19940124
			WO 1995-IE8	A 19950124

OTHER SOURCE(S): MARPAT 124:55584

GI For diagram(s), see printed CA Issue.

AB Calixarene-based compds., which are calixarenes or oxacalixarenes, acyclic phenyl-formaldehyde oligomers, cyclotrimeratrylene derivs., cyclic tetrameric resorcinol-aldehyde derivs. known as Hogberg compds. and cyclic tetrameric pyrogallol-aldehyde derivs., are prepared For example, calixarenes or oxacalixarenes are represented by general formula [I;  $n + m = 3-8$ ;  $m = 0-3$ ;  $n = 0-8$ ;  $R_1 = H$ , halo, hydrocarbyl, aryl, (un)substituted hydrocarbylaryl,  $NO_2$ ,  $SO_3M_1$ ; wherein  $M_1 = \text{alkali metal}$ ,  $SO_3H$ ;  $R_1 = OR_2$ ; wherein  $R_2 = CH_2CO_2R_3$ ,  $CH_2CO_2Mp/p$ ,  $CH_2CONR_4R_5$ ; wherein  $R_3 =$  (un)substituted alkyl;  $M = \text{metal}$ , ammonium ion;  $p =$  the charge on the metal ion;  $R_4$  or  $R_5$  may be the same or different, or both may be part of amino acid ester of poly(amino acid ester) or one or more of the same or different amino acids or part of a cyclic polyene antibiotic/antifungal drug or part of a cyclic nitrogen heterocycle;  $X = \text{halo}$ ,  $NO_2$ ,  $CO_2H$ , cyano, other electron withdrawing group]. Thus, n-butyraldehyde and pyrogallol in a 1:4 mixture of 37% aqueous HCl and EtOH was refluxed under N for 90 min to give a cyclic tetramer (II;  $R = X = H$ ), which was brominated with Br in  $CHCl_3$  to II ( $R = H$ ,  $X = Br$ ) and etherified with Et bromoacetate in the presence of  $K_2CO_3$  in refluxing acetone to give II ( $R = CH_2CO_2Et$ ,  $X = Br$ ). The latter compound was saponified with KOH in refluxing EtOH , acidified with aqueous HCl, and treated with 25% aqueous  $NH_4OH$  to give II ( $R = CH_2CO_2-NH_4^+$ ,  $X$

Br). The latter compound in vitro inhibited the infection of C8166 cells with HIV-2, SIV (Simian immunodeficiency virus), and HIV-1 with EC50 of 10, 20, and 0.03  $\mu$ M.



IT	171799-80-7P	171799-81-8P	171799-82-9P
	171799-89-6P	171799-90-9P	171799-91-0P
	171799-95-4P	171799-96-5P	171799-97-6P




RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of calixarene-based compds. having antibacterial, antifungal, anticancer, and anti-HIV activity)

RN 171799-80-7 CAPLUS

CN Acetic acid, 2,2',2'',2''',2''''',2''''',2''''',2''''',2''''',2''''',  
 ''',2''''''''',2'''''''''-[25,26,27,28-tetrabromo-2,8,14,20-(10-chloro-  
 9-anthracenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacos-  
 1(25),3,5,7(28),8,11,13(27),15,17,19(26),21,23-dodecaene-  
 4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis-,  
 dodecapotassium salt (9CI) (CA INDEX NAME)














●12 K




RN 171799-81-8 CAPLUS  
 CN Acetic acid, 2,2',2'',2''',2''''',2''''',2''''',2''''',2''''',2''''',2''''',  
 ''',2''''''''',2'''''''''-[[25,26,27,28-tetrabromo-2,8,14,20-(10-chloro-  
 9-anthracenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacos-  
 1(25),3,5,7(28),8,11,13(27),15,17,19(26),21,23-dodecaen-  
 4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis- (9CI)  
 (CA INDEX NAME)







RN	171799-82-9	CAPLUS
CN	Acetic acid, 2,2',2'',2''',2'''',2''''',2''''',2''''',2''''',2''''', ''',2''''''''',2'''''''''-[25,26,27,28-tetrabromo-2,8,14,20-(10-chloro- 9-anthracenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacos- 1(25'),3,5,7(28),8,11,13(27),15,17,19(26),21,23-dodecaene- 4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis-, dodecaammonium salt (9CI) (CA INDEX NAME)	







● 12 NH<sub>3</sub>

RN	171799-89-6	CAPLUS
CN	Acetic acid, 2,2',2'',2''',2'''',2''''',2''''',2''''',2''''',2''''', ''',2''''''''',2'''''''''-[25,26,27,28-tetrabromo-2,8,14,20-tetrakis(4- bromophenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacos- 1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene- 4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis-, dodecapotassium salt (9CI) (CA INDEX NAME)	





●12 K

RN	171799-90-9 CAPLUS
CN	Acetic acid, 2,2',2'',2''',2'''',2''''',2''''',2''''',2''''',2''''', ''',2''''''''''',2'''''''''''-[25,26,27,28-tetrabromo-2,8,14,20-tetrakis(4- bromophenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacos- 1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene- 4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis- (9CI) (CA INDEX NAME)



RN	171799-91-0	CAPLUS
CN	Acetic acid, 2,2',2'',2''',2'''',2''''',2''''',2''''',2''''',2''''', ''',2''''''''''',2'''''''''''-[25,26,27,28-tetrabromo-2,8,14,20-tetrakis(4- bromophenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacos- 1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene- 4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis-, dodecaammonium salt (9CI) (CA INDEX NAME)	







● 12 NH<sub>3</sub>



RN 171799-95-4 CAPLUS

CN Acetic acid, 2,2'',2''',2'''',2''''',2''''',2''''',2''''',2''''',2''''',  
 ''',2''''''''''',2'''''''''''-[[25,26,27,28-tetrabromo-2,8,14,20-tetrakis(4-  
 chlorophenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacos-  
 1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-  
 4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis-,  
 dodecapotassium salt (9CI) (CA INDEX NAME)





● 12 K

RN	171799-96-5 CAPLUS
CN	Acetic acid, 2,2',2'',2''',2'''',2''''',2''''',2''''',2''''',2''''', ''',2''''''''''',2'''''''''''-[25,26,27,28-tetrabromo-2,8,14,20-tetrakis(4-chlorophenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacosal(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis- (9CI) (CA INDEX NAME)



RN	171799-97-6	CAPLUS
CN	Acetic acid, 2,2',2'',2''',2'''',2''''',2''''',2''''',2''''',2''''', ''',2''''''''',2'''''''''-[[25,26,27,28-tetrabromo-2,8,14,20-tetrakis(4- chlorophenyl)pentacyclo[19.3.1.13,7.19,13.115,19]octacos- 1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene- 4,5,6,10,11,12,16,17,18,22,23,24-dodecayl]dodecakis(oxy)]dodecakis-, didecaammonium salt (9CI) (CA INDEX NAME)	



●12 NH<sub>3</sub>